Gravar-mail: Simultaneous reduction of flow and fraction of inspired oxygen (FiO(2)) versus reduction of flow first or FiO(2) first in patients ready to be weaned from high-flow nasal cannula oxygen therapy: study protocol for a randomized controlled trial (SLOWH trial)